ReviewCancer metastasis reviews2015
Targeted immune therapy of ovarian cancer.
Review in Cancer metastasis reviews, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed.
- Drug repositioning of disulfiram induces endometrioid epithelial ovarian cancer cell death via the both apoptosis and cuproptosis pathways.Oncology research · 2023Article
- Anhuienoside C inhibits human ovarian cancer cell growth by inducing apoptosis, suppression of cell migration and invasion, and targeting PI3K/AKT/mTOR signaling pathway.Molecular and cellular biochemistry · 2022Article
- Ovarian Cancer-Associated Ascites Have High Proportions of Cytokine-Responsive CD56bright NK Cells.Cells · 2021Article
- Identification of CXCL10-Relevant Tumor Microenvironment Characterization and Clinical Outcome in Ovarian Cancer.Frontiers in genetics · 2021Article
- Synergistic anti-tumor effect of anti-PD-L1 antibody cationic microbubbles for delivery of the miR-34a gene combined with ultrasound on cervical carcinoma.American journal of translational research · 2021Article
- TIGIT enhances CD4Cancer medicine · 2020Article
- Association between circadian geneOncology letters · 2018Article
- Development and evaluation of novel tumor-targeting paclitaxel-loaded nano-carriers for ovarian cancer treatment: in vitro and in vivo.Journal of experimental & clinical cancer research : CR · 2018Article
- Indirubin suppresses ovarian cancer cell viabilities through the STAT3 signaling pathway.Drug design, development and therapy · 2018Article
- Ultrasound-mediated microbubble destruction: a new method in cancer immunotherapy.OncoTargets and therapy · 2018Review
- Successful treatment of ovarian cancer with apatinib combined with chemotherapy: A case report.Medicine · 2017Article
- microRNA-494 is a potential prognostic marker and inhibits cellular proliferation, migration and invasion by targeting SIRT1 in epithelial ovarian cancer.Oncology letters · 2017Article
- Natural Killer Cells Response to IL-2 Stimulation Is Distinct between Ascites with the Presence or Absence of Malignant Cells in Ovarian Cancer Patients.International journal of molecular sciences · 2017Article
- Serum and peritoneal fluid concentrations of soluble human leukocyte antigen, tumor necrosis factor alpha and interleukin 10 in patients with selected ovarian pathologies.Journal of ovarian research · 2017Article
- Knockdown of USP39 induces cell cycle arrest and apoptosis in melanoma.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2016Article
- Prognostic significance of discoidin domain receptor 2 (DDR2) expression in ovarian cancer.American journal of translational research · 2016Article
- Network-based survival-associated module biomarker and its crosstalk with cell death genes in ovarian cancer.Scientific reports · 2015Article
- Increased expression of microRNA-196a predicts poor prognosis in human ovarian carcinoma.International journal of clinical and experimental pathology · 2015Article
Corrections and comments
- Retraction · 2016-05-30Duplication of Text ·
- Retracted
Authors and funding
4 authors.
Funding
Abstract
Clinical outcomes, such as recurrence-free survival and overall survival, in ovarian cancer are quite variable, independent of common characteristics such as stage, response to therapy, and grade. This disparity in outcomes warrants further exploration and therapeutic targeting into the interaction between the tumor and host. One compelling host characteristic that contributes both to the initiation and progression of ovarian cancer is the immune system. Hundreds of studies have confirmed a prominent role for the immune system in modifying the clinical course of the disease. Recent studies also show that anti-tumor immunity is often negated by immune regulatory cells present in the tumor microenvironment. Regulatory immune cells also directly enhance the pathogenesis through the release of various cytokines and chemokines, which together form an integrated pathological network. Thus, in the future, research into immunotherapy targeting ovarian cancer will probably become increasingly focused on combination approaches that simultaneously augment immunity while preventing local immune suppression. In this article, we summarize important immunological targets that influence ovarian cancer outcome as well as include an update on newer immunotherapeutic strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.